Tanvex BioPharma, Inc. (6541.TW) Stock

6541.TW logo

Tanvex BioPharma, Inc.

6541.TWCayman Islands
Healthcare

Company profile

Tanvex BioPharma reported revenue of 400.97 million TWD for fiscal year 2025, and a net loss of 1.50 billion TWD. That is a net profit margin of -374.1% for fiscal year 2025. United States was its largest region in fiscal year 2025, with 58% of revenue. Our analysis of its filings shows revenue growing from 61.41 million TWD in fiscal year 2023 to 400.97 million TWD in fiscal year 2025, 155.5% a year on average. Tanvex BioPharma reports about 215 full-time employees.

What stands out

  • Revenue more than tripled (up 1056.3%) in fiscal year 2025, from 34.68 million TWD in fiscal year 2024, after a fall of 43.5% the year before.
  • It reported a net loss in each of its last 5 fiscal years (2021 to 2025).
  • It spent 510.82 million TWD on research and development in fiscal year 2025, more than its revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.

Leadership

  • Allen Y. Chao Ph.D. — Founder & Honorary Chairman, 79
  • Angela Luan — CFO & Corporate Governance Officer
  • John R. Mosack — Chief Operating Officer of US
  • James Williamson — Chief Accounting Officer
  • Marc Goemans — Chief Commercial Officer

How much revenue does Tanvex BioPharma make?

Tanvex BioPharma reported 400.97 million TWD in revenue for fiscal year 2025, up 1056.3% from 34.68 million TWD in fiscal year 2024.

Where does Tanvex BioPharma make most of its revenue?

United States: 58% of revenue by region in fiscal year 2025, followed by Taiwan (42%).

What companies are similar to Tanvex BioPharma?

Listed companies of a similar size in the same industry (blood disorder treatment drugs) include PharmaEssentia Corporation (6446.TW).

How has Tanvex BioPharma's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 5.41 million TWD; FY2022, 22.40 million TWD; FY2023, 61.41 million TWD; FY2024, 34.68 million TWD; FY2025, 400.97 million TWD.

Has Tanvex BioPharma made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 1.54 billion TWD; FY2022, a loss of 1.64 billion TWD; FY2023, a loss of 2.14 billion TWD; FY2024, a loss of 1.38 billion TWD; FY2025, a loss of 1.50 billion TWD. It reported a net loss in each of these 5 years.

Company Information

SectorHealthcare
IndustryBlood Disorder Treatment Drugs
Employees215
FoundedJan 1, 2011
IPO DateOct 26, 2017
IPO StatusPublic
HeadquartersGeorge Town, Cayman Islands
FoundersAllen Chao
ExchangeTaiwan
TimezoneAsia/Taipei (CST)

Contact & Links

Address
802 West Bay Road, George Town, KY1-1205
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Tanvex BioPharma, Inc. (6541.TW)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/6541.TW

LinkedInLinkedInXXYouTubeYouTube